AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) have been given a consensus rating of “Moderate Buy” by the eleven ratings firms that are covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 12-month price target among brokers that have covered the stock in the last year is $51.10.

Several brokerages have recently commented on ANAB. Truist Financial boosted their price target on AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a research note on Thursday, August 15th. HC Wainwright reissued a “buy” rating and set a $55.00 price target on shares of AnaptysBio in a research note on Wednesday, August 14th. Wedbush reissued an “outperform” rating and set a $42.00 price target on shares of AnaptysBio in a research note on Thursday, September 26th. Finally, JPMorgan Chase & Co. boosted their price target on AnaptysBio from $69.00 to $75.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th.

AnaptysBio Trading Down 3.0 %

NASDAQ ANAB opened at $33.98 on Friday. The business’s 50 day moving average is $35.45 and its two-hundred day moving average is $28.50. AnaptysBio has a 12-month low of $13.36 and a 12-month high of $41.31. The stock has a market capitalization of $928.30 million, a price-to-earnings ratio of -5.53 and a beta of -0.29.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.82). AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.25%. The business had revenue of $10.97 million for the quarter, compared to analyst estimates of $25.85 million. Equities analysts forecast that AnaptysBio will post -6.84 earnings per share for the current fiscal year.

Insider Activity at AnaptysBio

In related news, insider Paul F. Lizzul sold 1,500 shares of the company’s stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $38.67, for a total value of $58,005.00. Following the sale, the insider now owns 15,398 shares of the company’s stock, valued at approximately $595,440.66. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other AnaptysBio news, insider Paul F. Lizzul sold 1,500 shares of the stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $38.67, for a total transaction of $58,005.00. Following the transaction, the insider now owns 15,398 shares of the company’s stock, valued at $595,440.66. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Eric J. Loumeau sold 8,720 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $39.82, for a total value of $347,230.40. Following the transaction, the insider now directly owns 7,020 shares in the company, valued at approximately $279,536.40. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 33,940 shares of company stock valued at $1,251,836. 33.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Allspring Global Investments Holdings LLC purchased a new position in shares of AnaptysBio during the 1st quarter worth $38,000. Headlands Technologies LLC lifted its stake in shares of AnaptysBio by 444.8% during the 2nd quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock worth $89,000 after purchasing an additional 2,900 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in shares of AnaptysBio by 66.8% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 5,123 shares of the biotechnology company’s stock worth $115,000 after purchasing an additional 2,051 shares during the period. Virtu Financial LLC purchased a new position in shares of AnaptysBio during the 1st quarter worth $222,000. Finally, Algert Global LLC increased its holdings in shares of AnaptysBio by 11.8% during the 2nd quarter. Algert Global LLC now owns 10,178 shares of the biotechnology company’s stock worth $255,000 after buying an additional 1,078 shares during the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.